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SLC7A9 mutations in all three cystinuria subtypes. Cystinuria (MIM 220100) is a common heritable disor-
Background. Cystinuria is an inherited disorder of cystine der due to the defective transport of cystine and dibasic
and dibasic amino acid transport in kidney. Subtypes are de-
amino acids across the epithelial cells of the renal tubulefined by the urinary cystine excretion patterns of the obligate
and the intestinal brush border. Precipitation of cystineheterozygous parents: Type I/N (fully recessive or silent); Type
II/N (high excretor); Type III/N (moderate excretor). The first at the acidic pH of collecting duct fluid results in forma-
gene implicated in cystinuria (SLC3A1) is associated with the tion of microcrystals that frequently coalesce into larger
Type I urinary phenotype. A second cystinuria gene (SLC7A9)
calculi, obstructing the urinary tract and predisposing towas recently isolated, and mutations of this gene were associ-
infection and renal insufficiency.ated with dominant (non-Type I) cystinuria alleles. Here we
report genotype-phenotype studies of SLC7A9 mutations in a Pras et al demonstrated linkage to a locus on chromo-
cohort of well-characterized cystinuria probands and their fam- some 2p [1], in the same area as the SLC3A1 (rBAT) gene
ily members.
(MIM 104614) [2]. This gene had been previously clonedMethods. Individual exons of the SLC7A9 gene were screened
by Lee et al [3] and Bertran et al [4], and its rat and rabbitby single strand conformation polymorphism (SSCP) analysis
and sequencing of abnormally migrating fragments. orthologs have been shown to be amino acid transporters
Results. Seven mutations were identified. A single bp inser- [5–7]. Calonge et al established that the SLC3A1-encoded
tion (799insA) was present in four patients: on Type III alleles
663-amino acid heavy subunit of the transporter is defec-in two patients and on Type II alleles in two patients. These re-
tive in cystinuria [2]. Over 40 mutations have been re-sults suggest that Type II and Type III may be caused by the
same mutation and, therefore, other factors must influence uri- ported in this gene [8]. Heterozygotes, with presumably
nary cystine excretion. A 4bp deletion in intron 12 (IVS124- 50% of SLC3A1 function, excrete cystine in the normal
delAGTA) and a missense mutation (1245G→A, A354T) were
range [9].identified on Type III alleles. A nonsense codon (1491G→T,
Three types of cystinuria have been described, based onE436X) and a possible splicing mutation (IVS9-17G→A) were
seen in a Type I/III patient, but the mutations could not be as- the level of urinary cystine in obligate heterozygotes. Type
signed to particular alleles. Of additional interest were two I/N heterozygotes excrete cystine at normal levels (0 to
missense mutations (316T→C, I44T and 967C→T, P261L) linked
100 mol cystine/g creatinine), whereas Type II/N andto Type I alleles.
Type III/N heterozygotes exhibit high or moderate ex-Conclusion. Our results provide evidence that some SLC7A9
mutations may be associated with fully recessive (Type I) forms cretion (900 or 100 to 900 mol cystine/g creatinine),
of cystinuria. We also demonstrate SLC7A9 mutations in domi- respectively [10]. Only in Type II/N heterozygotes is the
nant Types II and III cystinuria. The finding of SLC7A9 muta-
cystine excretion high enough to put them at risk fortions in all three subtypes underscores the complex interactions
stone formation. Offspring who inherit two mutant cysti-between specific cystinuria genes and other factors influencing
cystine excretion. A simpler phenotypic classification scheme nuria genes excrete much higher levels of cystine, often
(recessive and dominant) for cystinuria is warranted. exceeding its solubility threshold.
The three cystinuria phenotypes were initially attrib-
uted to allelic variants of the same gene but family studies
suggestive of “genetic complementation” between Type I
and Type III cystinuria prompted the hypothesis thatKey words: amino acid, transport, inherited disorder, genetics, kidney,
stone, mutation, microcrystals. there might be multiple genes involved [11]. Calonge et
al demonstrated homogeneity for linkage of “classic”
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known SLC3A1 mutations have been associated with Ontario, Canada), Life Technologies and Fermentas
(Burlington, Ontario, USA). The [-35S]dATP (12.5 ci/the fully recessive (Type I) form of cystinuria [9].
In 1999, the International Cystinuria Consortium cloned mol) was supplied by Dupont (Wilmington, DE, USA).
The Geneclean III kit was purchased from Bio 101SLC7A9, a second cystinuria gene (MIM 604144) [13].
It resides on chromosome 19q between microsatellite (Vista, CA, USA) and the T/A Cloning Kit from Invitro-
gen (Carlsbad, CA, USA). The Qiaprep Spin Miniprepmarkers D19S776 and D19S786, in the refined locus that
they had defined for non-Type I cystinuria. SLC7A9 and DyeEx Spin kits were from Qiagen (Mississauga,
Ontario, Canada). Sequenase kits were obtained fromencodes a 487-amino acid protein, termed bo,AT, which
belongs to a family of light subunits of amino acid trans- United States Biochemicals (Oakville, Ontario, Canada)
and Big Dye Terminator Cycle Sequencing kit V2.0 wasporters. Cotransfection of bo,AT with rBAT resulted in
the proper localization of the latter in the plasma mem- from Applied Biosystems (Foster City, CA, USA).
brane, and in the uptake of l-arginine into COS cells;
Identification of mutationsthese cells are a fibroblast-like cell line established from
CV-1 simian cells from kidney of the African green mon- We used public genomic DNA sequence databases for
the establishment of solid guidelines for SLC7A9 genekey. In contrast, transfection of rBAT alone resulted in
the arrest of the expressed protein in the endoplasmic structure. High-throughput sequencing of the BAC clone
CITB-HI_2085J24 by the Doe-Joint Genome Institutereticulum. The International Cystinuria Consortium iden-
tified the first mutations in the SLC7A9 gene [13]. Libyan (GenBank Accession No. AC008805) revealed relevant
preliminary sequence information for design of PCR prim-Jewish patients were homozygous for a founder missense
mutation. In other patients, two frameshift mutations and ers. We independently confirmed (GenBank Accession
Nos AF421170 to AF421181) the sequence of SLC7A9four missense mutations were identified. More recently,
28 other SLC7A9 mutations in non-Type I cystinuria coding exons and their boundaries. They were analyzed
as 12 segments that were subjected to polymerase chaincases were reported [14].
The present study was undertaken to identify SLC7A9 reaction (PCR)-dependent heteroduplex and single-strand
conformational polymorphism (SSCP) analysis.mutations in cystinuria patients who have been carefully
classified into the three phenotypic subtypes, on the basis Single-strand conformational polymorphism (SSCP)
and heteroduplex analyses were carried out as describedof the excretion pattern of obligate heterozygous par-
ents. Our analysis addresses the difficult question of ge- previously [9]. PCR for twelve segments (designated I
to XII), encompassing all SLC7A9 coding exons (re-notype/phenotype correlations in this complex genetic
disease. ported as exons 2 to 13 [14]) and their surrounding se-
quences, was performed. PCRx Enhancer Solution was
used at concentration 1X to amplify segment I with Plati-
METHODS
num Taq DNA polymerase. Other segments were ob-
Patients tained with Taq DNA polymerase using the manufac-
turer-recommended buffer. Primers used were describedThirteen unrelated patients were identified by the
Quebec Network of Genetic Medicine newborn urinary in the supplementary Table B of [14] (http://hmg.oup
journals.org/cgi/data/10/4/305/DC1/1), except for threescreening program. Patients were classified into cystin-
uria subtypes on the basis of urinary excretion patterns primers: sense primer of fragment I, SLC7A9E2-F2,
5-TGTGCGCCCTCCTTGCAGT-3; reverse primer ofof obligate heterozygous parents, as previously described
[10]. All these patients but one (I/I phenotype) are ex- fragment IV, SLC7A9E5-R2, 5-TGCTTCCTTGGAGA
TGGGCT-3; and sense primer of fragment V, SLC-pected to carry at least one dominant or semi-dominant
(Type II or Type III) allele. Relevant biochemical data 7A9E6-F2, 5-TCCCGTGGAGATACACTCA-3. PCR
products were verified by acrylamide gel electrophoresis,are presented in Table 1 for the eight patients who were
shown to carry mutations in SLC7A9. We did not find allowing for potential heteroduplex formation to be visu-
alized before undergoing SSCP. Fragments displayingany evidence for mutations in SLC7A9 in the other five
patients. shifts by SSCP or heteroduplex analysis were sequenced
directly or subcloned and sequenced. Sequencing was
Materials performed on both strands using the primers of the initial
PCR amplification, with Sequenase kits or by fluores-Oligonucleotide primers were synthesized by the Shel-
don Biotechnology Center (McGill University, Mont- cence-based automated analysis on an ABI-310 PRISM
Genetic Analyzer (Applied Biosystems).real, Canada) and ACGT (Toronto, Ontario, Canada).
Taq DNA polymerase, Platinum Taq DNA polymerase
Confirmation of mutationsand PCRx Enhancer Solution were purchased from Life
Technologies (Burlington, Ontario, Canada). Restriction The confirmation of mutations in genomic DNA was
made by PCR-dependent diagnostic tests. These testsenzymes were from New England Biolabs (Mississauga,
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Table 1. Summary of phenotypes and SLC7A9 mutations in cystinuria familiesa
Urinary cysteinea
Patients and parents Familial position lmol/g creatinine Type Mutations
CH (1940-02) proband 1518 I/III ?/IVS124delAGTAb
GH (1940-01) father 36 I/N ?
LC (1940-03) mother 250 III/N IVS124delAGTA
AW (872-01) proband 2714 I/IIId IVS9-17G→A/E436X
RW father 29 I/N —
EW mother 306 III/N —
DR (918-01) proband 860 II/Nd 799insA/N
DR father 1100 II/N —
EW mother 40 N/N —
KD (1875-01) proband 2514 III/III 799insA/?
RL father 183 III/N —
DD mother 236 III/N —
MS (1245-03) proband 1447 I/II P261L/799insA
SS (1245-02) father 50 I/N P261L
JS (1245-01) mother 1476 II/N 799insA
GF mat. grandfather 1741 II/Nd —
PD (1390-01) proband 1298 I/III ?/799insA
PD father 402 III/N 799insAc
KM (1390-02) mother 78 I/N ?
CL (988-01) proband 658 III/N A354Tb/N
RL father 30 N/N —
LC mother 577 III/N —
DH (1898-03) proband 1013 I/I I44T/?
CH (1898-02) father 56 I/N I44T
RR (1898-01) mother 46 I/N ?
a For proband, average of 5 to 8 values from age 2 to 10 years. For the family members without a number, DNA was not available; urinary values may be single
values or an average.
b These mutations were also recently identified in unrelated cystinuria patients [14]
c DNA not available from father. Assumed to carry this mutation since mother was negative.
d Kidney stones
examined the creation or destruction of a particular re- PCR was carried out using 2 L template, 250 ng each
specific primer, 1 L each dNTP (from a 10 mmol/Lstriction site due to a specific mutation. The oligonucleo-
tides used for diagnostic tests are listed in Table 2. Some stock) and 3 U Taq polymerase in a 50 L volume.
Digestion was carried out using 5 to 16 L of the PCRof these primers also were used for SSCP analysis (de-
scribed in the previous paragraph). If the mutation did product with the appropriate restriction enzyme for 3 to
16 hours at the required temperature before subjectingnot change a restriction site, one was created through
the use of an oligonucleotide in which one of the 3 end the samples to electrophoresis on an 8% acrylamide gel.
For each of the mutations resulting in a nucleotide substi-nucleotides was altered. This altered oligonucleotide
generated an artificially-created restriction site (ACRS) tution and where the result did not lead to a stop codon,
at least 50 control samples were analyzed for mutationswhen found in combination with a specific allele, cutting
the appropriate PCR product to generate the expected to ensure that they were not common polymorphisms.
fragments (ACRSDdeI: 5-GCTTCATTACAGGAAA
Computer analysis of splicing mutationsCACTAA-3, ACRSMseI: 5-ATGGGCTCAGAAAA
TCTCAATTA-3 and ACRSSduI: 5-TTGGCCATTA Computer analysis of the strength of splice sites of ge-
TCATCGGGAGCC-3). Underlined letters indicate the nomic sequences spanning relevant nucleotides was per-
nucleotides that were altered to create a new restriction formed using programs from the Individual Information
site in combination with downstream sequence. The primer package of Schneider [15]. Programs used included de-
MnlIsense 5-GTCTCCGTGTCATTGCCTCTC-3 was lila, scan, exon, and lister. These are a few of the mem-
designed to avoid the interference of other MnlI seg- bers of the large Delila package [16] (from the Labora-
tory of Computational and Experimental Biology at thements in the diagnostic assays. Primers SLC7A9E5-R3:
5-GGTGAAGATGTTCTGGACGTA-3 and ACRS- National Institutes of Health, http://www.lecb.ncifcrf.gov/
toms/). Scan calculates the strengths of splice donor andBstUI 5-CTGGCCCAAGGTGACCCGC-3 were used
to confirm variants that were observed in cystinuria pa- acceptor sites, and lister displays the results.
Values of the Individual Information variable Ri(b, l, j)tients as well as in normal controls (Table 3). Genomic
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Table 2. Strategies for PCR-based diagnostic tests of mutations identified in SLC7A9 gene of cystinuria patientsa
Expected size after digestione bp
Expected sized Restriction
Mutationb Primersc bp enzyme used Normal Mutant Figuref
IVS124delAGTAg SLC7A9E12-F/SLC7A9E12-R 370 — — heteroduplex 1A
IVS124delAGTAh ACRSMseI/SLC7A9E12-R 96 MseI 75,21 92 —
1491G→T (E436X) SLC7A9E12-F/SLC7A9E12-R 370 SexAI 370 195,175 1B
IVS9-17G→A SLC7A9E10-F/SLC7A9E10-R 210 NlaIII 110,100 100,62,48 1C
799insA ACRSDdeI/SLC7A9E6-R 177 DdeI 104,54,19 124,54 1D
967C→T (P261L)g MnlIsense/SLC7A9E8-R 225 MnlI 123,64,26,12 123,40,26,24,12 1E
967C→T (P261L)h ACRSSduI/SLC7A9E8-R 190 SduI or Bsp1286I 101,67,22 123,67 1F
1245G→A (A354T) SLC7A9E10-F/SLC7A9E10-R 210 AciI 65,52,40,30,23 95,52,40,23 1G
316T→C (I44T) SLC7A9E3-F/SLC7A9E3-R 238 TspRI 194,44 164,44,30 1H
a These mutations were absent from panels of normal controls
b Cystinuria patients that are positive for these mutations are listed in Table 1
c Sense/antisense primers used for PCR; sequences or relevant citation are given in the Methods section
d Size of undigested PCR product for normal allele
e Expected sizes of cleavage products for homozygotes. Heterozygotes will contain a mixture of normal and mutant patterns.
f Refers to panels in Figure 1
g Diagnostic test designed for identification and confirmation of the mutation
h Assay performed for testing the absence of this mutation in normal DNA samples
Table 3. Polymorphisms identified in SLC7A9 gene and PCR-based diagnostic testsa
Expected size after
digestionc bp
Expected size Restriction
Variant Primersb bp enzyme used Normal Mutant
413G→C (A76A) SLC7A9E3-F/SLC7A9E3-R 238 NruI 165,73 238
IVS322T→G SLC7A9E3-F/SLC7A9E3-R 238 BstNI 226,12 193,33,12
596T→C (C137C) SLC7A9E4-F/SLC7A9E4-R 388 BstUI 388 258,130
692C→T (S169S) SLC7A9E5-F/SLC7A9E5-R3 130 AdeI 130 92,38
IVS510G→A ACRSBstUI-F/SLC7A9E5-R2 110 BstUI 92,18 110
852C→A (L223M) SLC7A9E6-F2/SLC7A9E6-R 232 BstNI 130,85,17 215,17
872C→T (L229L) SLC7A9E6-F2/SLC7A9E6-R 232 HinfI 146,44,42 190,42
1328T→C (A381A) SLC7A9E11-F/SLC7A9E11-R 252 TseI 229,23 137,92,23
1550C→T (V455V) SLC7A9E12-F/SLC7A9E12-R 370 XcmI 267,103 370
a These mutations were found in normal controls and in cystinuria patients
b Sense/antisense primers used for amplification; sequences or relevant citations are described in the Methods section
c Expected sizes for homozygotes; heterozygotes show a mixture of normal and mutant patterns
are calculated for each base and position of the selected RESULTS
sequence, j, in the range of interest. In this situation, Table 1 summarizes the phenotypes and SLC7A9 mu-
Ri(b, l, j) is the difference in uncertainty before and after tations of patients and available parents. Table 2 pro-
binding of a specific base, b, at a specific position, l, rela- vides the details of the diagnostic procedures used to
tive to the origin of an acceptor or donor sequence, j. confirm mutations.
Site values are the sum of these contributions over the
appropriate range of bases. Sufficiently large site values Patient CH (1940-02, Type I/III)
indicate potentially functional sites [17]. Walkers illus-
In this child, a heteroduplex pattern in segment XItrate the Individual Ri contributions of the bases to the (370 bp) was found to be due to a deletion of 4 bp in in-acceptor or donor site at a location. On these plots, bases
tron 12, IVS124delAGTA (Fig. 1A). The deletion wasthat contribute positively to the Ri sum point upward,
characterized by sequencing independent subclones gen-those that contribute negatively point down. The height
erated from PCR products that yielded the heteroduplexof the letter is proportional to the information contribu-
pattern. The mutation was confirmed using a ACRS-tion of that base. The Ri sum is given along with the
based MseI diagnostic test where 21 bp are removedtype of site for which it is calculated. The programs were
from the 96 bp normal allele after digestion, leaving therun on a Sun SPARCstation 2 under Sun OS 5.5.
92 bp mutant amplicon undigested (data not shown).Neural Network analysis of relevant sequences was
MseI digestion, heteroduplex analysis and direct se-also performed [18] (http://www.fruitfly.org/seq_tools/
quencing of the PCR product (data not shown) revealedsplice-instrucs.html). Furthermore, normal and mutant
that CH (1940-02), a Type I/III patient, is heterozygoussplice sites were compared to the consensus sequences
defined by Senapathy, Shapiro and Harris [19]. for the change. His mother (LC, 1940-03, type III/N) is
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Fig. 1. DNA diagnostic tests for mutations in SLC7A9. Fragments were amplified using primers indicated in Table 2, digested with appropriate
restriction enzymes (except in A) and analyzed by acrylamide gel electrophoresis. The letter C above the lanes stands for controls. The asterisks
indicate bands that are specific for the mutated alleles. Image E is an autoradiogram. All other gels were stained with ethidium bromide. (A)
Detection of heteroduplexes caused by IVS124delAGTA in segment XI for two members of family 1940. (B) SexAI digestion of proband AW
(872-01) and two controls for the 1491G→T mutation (E436X). Only the mutant PCR fragment contains a SexAI site that cleaves the fragment
of 370 bp into 195 bp and 175 bp fragments. (C ) NlaIII digestion of segment IX for AW (872-01) and three controls. The presence of mutation
IVS9-17G→A is shown by bands of 62 bp and 48 bp. (D) DdeI digestion of probands DR (918-01), PD (1390-01) and two controls for the 799insA
mutation. The mutation obliterates a DdeI site encompassing the 3end of the modified PCR primer. DdeI normally cleaves twice in the 177 bp
product, generating bands of 104, 54 and 19 bp (the 19 bp fragment is not seen on this gel). In the absence of one of these restriction sites, a
fragment of 124 bp (that contains an extra base) is seen in probands. (E ) MnlI restriction analysis of a 225 bp PCR product. The mutation 967C→T
(P261L) results in the creation of an extra MnlI site in the amplicon, visible as a 40 bp band specific to the mutant allele. (F ) SduI digestion of
proband MS (1245-03) and two controls for diagnostic of the 967C→T (P261L) mutation. Only the control PCR fragments results in an artificially-
created SduI site, making the 123 bp segment specific for the mutant allele. (G) AciI restriction analysis of segment IX PCR products. The
1245G→A (A354T) mutation abolishes one of the four AciI restriction sites in the PCR product of patient CL (988-01). (H ) Diagnostic for the
316T→C (I44T) mutation found in DH (1898-03). The mutation results in the creation of a second TspRI site in the 238 bp fragment II.
also heterozygous for this mutation while his father (GH, to a splicing defect. According to the information theory
model, the mutation is predicted to abolish splicing1940-01) is negative (Fig. 1A). Therefore this mutation
is associated with the Type III phenotype. The second (Fig. 2C) since the Ri value is inferior to the threshold
of 2.4 bits [17].mutation in this patient has not yet been identified.
The four deleted bases can be seen as one unit of a
Patient AW (872-01, Type I/III)direct repeat of four bases (Fig. 2A). This mutation re-
sults in a modification of the context surrounding the In this child, an extra band was detected through SSCP
natural 5 splice site. Comparison with Senapathy’s com- analysis of segment XI, which encompasses exon 12. This
pilations (Fig. 2B), as well as Neural Network analysis extra band proved to be caused by a nonsense mutation,
1491G→T (E436X), which should result in the trunca-(Fig. 2C), suggests that IVS124delAGTA should lead
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Fig. 2. Deletion of four bp in patient CH (1940-02). (A) Sequence surrounding the mutated site. The vertical bar shows the exon 12/intron 12
junction. The two boxes show the direct repeat of four bases. (B) Comparison of the normal and mutant sequences to the consensus donor site.
The optimal donor site sequence was deduced from 3724 compiled 5 splice sites [19]. The nucleotide frequencies observed by Senapathy et al
[19] at each position are shown under the sequences as a percentage. (C ) Donor site evaluation for normal and mutant sequences, based on
Neural Network analysis method [18] or information theory model [15]. Splice sites sequences are shown by sequence walkers, in which the height
of each letter is the contribution of that base to the total information of the site (in bits) [16]. The upper boundary of the vertical rectangles is at
2 bits, and the lower boundary is at 3 bits. Letters that are upside down represent negative contributions. The top walker diagram depicts the
natural splice site and the lower one corresponds to the mutated sequence. The deletion substantially lowers the Ri value of the donor site, making
it non-functional [17].
tion of 52 amino acids at the C-terminal; this region ever, we cannot exclude the possibility that this change
has a more severe impact than predicted, since it is lo-includes the last putative transmembrane domain and
the C-terminus of bo,AT [13]. The mutation creates a cated within a long polypyrimidine tract, between the
branchpoint sequence and the acceptor site (Fig. 3). Forsingle SexAI site not present in the normal sequence
(Fig. 1B). The patient is heterozygous for this mutation. example, it could lead to an alteration of secondary struc-
ture that interferes with the splicing machinery, or itAn additional band in the SSCP pattern for segment
could have an influence on a splicing enhancer. TheseIX of the same patient (AW) proved to be caused by
types of effects would be compatible with the mild defectanother point mutation, IVS9-17G→A, also in the het-
expected for a Type I allele of a Type I/III proband.erozygous state in the patient. This mutation, identified
through direct sequencing of the PCR product, is located
Patients DR (918-01, Type II/N), KD (1875-01,in an intronic segment containing elements that influence
Type III/III), MS (1245-03, Type I/II) andsplicing (Fig. 3). The mutation creates a second NlaIII
PD (1390-01, Type I/III)site in the 210 bp genomic segment (Fig. 1C). Because
the father has British ancestors, we verified the absence In these patients, a band was observed on SSCP gels
of amplified segment V. After subcloning the PCR prod-of the mutation in a panel of 50 British controls in addi-
tion to our standard set of 51 controls from Quebec (data uct, it was found to contain an insertion of one bp in
exon 6 between nucleotides 799/800 of the cDNA se-not shown). The Scan program predicts a slight decrease
in the information content of the acceptor site for muta- quence, adding an extra adenosine to a stretch of three
consecutive adenosines (data not shown). It is predictedtion IVS9-17G→A, which is not predicted to have a
significant effect on splicing (data not shown). The muta- to change the reading frame of the cDNA, creating a
downstream termination signal. The mutation was con-tion does not create new donor or acceptor sites. How-
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Fig. 3. Context associated with mutation IVS9-17G→A. The G→A change is shown at position 17, between the 3 splice junction and the
potential branchpoint sequence [20].
firmed using a modified sense primer, by testing for the
presence of a DdeI restriction site specific to the normal
177 bp genomic segment (Fig. 1D). The mutation was
found to be heterozygous in all four patients. For MS
(1245-03) and PD (1390-01), we showed that the frame-
shift mutation was transmitted to the probands by the
mother and the father, who have Type II and Type III
phenotypes, respectively (data not shown).
Patient MS (1245-03, Type I/II)
In this patient, a second mutation was seen as an extra
band during SSCP analysis of segment VII. DNA se-
quencing revealed that the extra band was caused by the
point mutation 967C→T (P261L), which creates a MnlI
site. However, we could not use the SSCP primers to per-
form a MnlI-diagnostic test, because MnlI digestion of
the SSCP fragment generates bands that interfere with
Fig. 4. Pedigree and SLC7A9 subtypes for family 1245. Fully-black-
the diagnostic assay (data not shown). The mutation cre- ened symbols denote dominant cystinuria. Dotted boxes contain urinary
cystine level (mol cystine/g creatinine), type of cystinuria and SLC7A9ates a fourth, detectable MnlI restriction site when we
mutations. The maternal grandfather was a severe cystinuria case withamplified a 225 bp genomic segment (Table 2 and Fig.
stones. Because DNA was not available for the grandfather, the muta-
1E). DNA from his British father (SS, 1245-02) showed tion shown (799insA/N) is predicted from data obtained from the pro-
band and his mother.the same change (Fig. 1E), which was absent in a set of
50 British controls as well as the 51 Quebec controls.
Although the MnlI diagnostic assay was useful for con-
firming the mutation, it was technically difficult, requir-
point mutation, 316T→C (I44T), identified through di-ing radioactive PCR products to achieve the required
rect sequencing of the amplified segment. This mutationsensitivity. For these reasons, the mutation 967C→T also
creates a second TspRI site in the 238 bp DNA segmentwas confirmed through another diagnostic test (ACRS-
(Fig. 1H). The patient’s father (CH, 1898-02, I/N) wasbased), which takes advantage of the loss of one of the
positive for the same mutation (data not shown). Thetwo SduI sites in the mutant PCR segment (Table 2 and
maternal mutation is unknown. The I44T mutation wasFig. 1F). The isoschyzomer Bsp1286I was used also and
not observed in our panel of controls.showed the same results (data not shown).
Patient CL (988-01, III/N)
DISCUSSION
Here, an extra band was detected during SSCP analysis
For clinical purposes, the classification of cystinuriaof segment IX. The band was due to an exon 10 missense
has been based on urinary phenotype that presumablymutation, 1245G→A (A354T), found by direct sequenc-
reflects the severity of the proximal tubular transporting of PCR products (not shown). The mutation was con-
defect. More specifically, the urinary cystine levels offirmed through an AciI-based test (Table 2 and Fig. 1G).
obligate heterozygous parents have been used to distin-CL proved to be heterozygous for this mutation (AciI
guish three subtypes [11]. Initially, it was postulated thatdigestion and sequencing data, not shown).
the variations among the Types I, III and II cystinuria
Patient DH (1898-03, Type I/I) subtypes might be explained by mild, moderate or se-
vere mutations at a single locus. However, the identifica-In this child, an extra band was discovered during
SSCP analysis of segment II. The band was caused by a tion of multiple mutations in two genes—SLC3A1 and
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SLC7A9—and the potential candidature of a third cys- had also been identified in non-Type I patients by the
International Consortium. The quantitative informationtinuria-causing gene, SLC7A10 [21], indicate that the
genetics is more complex than originally anticipated. analysis, summarized in Figure 2, predicts that the in-
tronic change is likely to abolish splicing. The A354TMutations in SLC3A1 thus far have been associated
only with Type I alleles, primarily in patients with classi- mutation had been expressed by the aforementioned
group and shown to abolish cystine transport. The E436Xcal Type I/I cystinuria that displays autosomal recessive
inheritance (normal excretion pattern in the obligate mutation, a nonsense mutation in a Type I/III proband,
is likely to be quite severe, but it could not be assignedheterozygous parents). The International Cystinuria Con-
sortium recently isolated the SLC7A9 gene and identi- to a phenotype since parental DNA was not available.
We suggest, however, that it might be linked to thefied mutations in this gene only in non-Type I cystinuria
patients. Our study of SLC7A9 mutations is consistent Type III allele, since the SLC7A9 mutations on a Type I
(silent) recessive allele may be milder than those associ-with a major role for this gene in non-Type I cystinuria,
but also suggests that SLC7A9 mutations may account ated with the dominant Type III allele (discussed later
in this article).for some Type I alleles of mixed phenotype probands
(Type I/non-Type I) and of non-classic Type I/I probands. In an earlier study of cystinuria, we examined our
patients for mutations in SLC3A1. We found that muta-Taken together, these results suggest that SLC7A9 muta-
tions cause a wide spectrum of urinary cystine levels. tions in SLC3A1 accounted for virtually all the mutations
in nine classical Type I/I patients with autosomal reces-We identified one specific mutation, 799insA, in het-
erozygotes of two families exhibiting a dominant pattern sive inheritance [9], which is characterized by very high
cystine excretion (range 2578 to 5778 mol cystine/g cre-of cystine excretion in the stone-forming (Type II/N)
range, and in two families with a dominant pattern of atinine [10]). In the mixed phenotype patients (Types I/
III), our mutation detection rate for SLC3A1 was consid-moderate (Type III/N) cystinuria. This SLC7A9 frame-
shift should lead to premature termination of translation, erably lower, prompting us to suggest that some Type I
mutations might occur in genes other than SLC3A1. Ina finding that is consistent with a non-functional polypep-
tide. Since the same null mutation may cause either mod- the current study, we identified SLC7A9 mutations in
two patients with mixed phenotypes (Type I/non-Type I)erate or severe cystinuria in different families, factors
other than the SLC7A9 mutation clearly influence the and in one patient with Type I/I cystinuria; two of these
mutations are clearly linked to the Type I allele whilelevel of cystine excretion. Similar conclusions were re-
ported by the International Cystinuria Consortium [14]. one mutation could not be phased. The International Cys-
tinuria Consortium also has recently identified SLC7A9Nephrolithiasis, the secondary consequence of cysti-
nuria, involves an additional level of inter-individual mutations linked to the Type I allele (M. Palacin, mem-
ber of Consortium, unpublished results).variability. Thus far, all known SLC3A1 mutations ex-
hibit a recessive urinary phenotype, yet Schmidt et al In the Type I/I proband (DH; 1898-03), we identified
the I44T missense mutation which was inherited fromreported sibs with identical homozygous SLC3A1 muta-
tions whose first stones appeared at ages ranging from 9 his father, a Type I (silent) carrier. This mutation was
not present in a large series of controls. The isoleucineto 22 years [abstract; Schmidt et al, Am J Hum Genet
69(Suppl):474, 2001]. Although cystinuria genes may be codon is completely conserved among members of the
family of light subunits of heteromeric amino acid trans-powerful determinants of the cystine excretion level, the
risk of nephrolithiasis also may depend on modifiers of porters (alignment shown in [13]) as well as in the protein
product of the recently identified SLC7A10 gene, an-cystine precipitation or microcrystal aggregation at the
tubular wall. other potential candidate gene for cystinura (alignment
in [21]). Although expression studies should be per-During the course of our work, the International Cys-
tinuria Consortium described a frequent mutation (which formed to confirm the deleterious nature of the substitu-
tion, the data thus far suggest that the mutation is notthey designated as c.800-801insA) in non-Type I patients,
resulting from insertion of an adenosine at the neigh- a benign polymorphism. A putative splicing mutation in
SLC7A10, which is homologous to SLC7A9 and is lo-boring base [14]. Our DdeI diagnostic test confirms that
the extra adenosine found in our patients is present after cated within the same chromosomal region, was also
identified in this patient; it had been inherited from hisposition 799 and not after position 800. Whether these
two mutations are identical remains to be determined. father (proband number is 1869-1 in [21]). As discussed
in that study, two mutations might be required to exhibitThree of the other identified SLC7A9 mutations in
our patients also are likely to have severe consequences: a phenotype. Relevant to this finding is the observation
that SLC7A9 mutations A354T and A182T were foundthe IVS124delAGTA splicing mutation, the A354T
missense mutation, and the E436X nonsense mutation. on a single allele by the International Consortium with
negligible and partial transport activity, respectively [14].The splicing and missense mutations are clearly linked to
a Type III phenotype in our families; these two mutations This Type I/I proband (DH; 1898-03) has a much lower
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level of cystine excretion (average, 1013 mol cystine/g genes. These patients may harbor promoter mutations,
creatinine) compared to the aforementioned level usu- intronic changes creating or enhancing cryptic splice
ally seen in classic Type I/I probands with homozygous sites, as well as large genomic rearrangements in either
mutations of SLC3A1. A mutation in SLC7A9, instead of the known cystinuria genes. However, the involve-
of SLC3A1, may be associated with a milder phenotype ment of a third gene is a distinct possibility. SLC7A10
in Type I/I patients. mutations have been reported [21] but other genes are
The other SLC7A9 change observed on Type I allele likely to be identified. The recent review by Chillaron
is a P261L mutation observed in a father [Type I (silent) et al discusses the opposite gradients of expression ob-
carrier] and in his cystinuric son (patient MS; 1245-03). served for bo,AT and rBAT along the kidney proximal
Again, this mutation was not observed in a large panel tubule, and promotes the hypothesis of additional genes
of controls and the residue is conserved to the same [22]. Careful biochemical characterization of patients
extent as described above for the I44T change. In addi- and their families, combined with molecular biologic
tion, because proline is an imino acid, substitution of studies, should continue to clarify the complex genetics
a proline is believed to be deleterious because of the of this transport disorder.
secondary rather than a primary amino group. Presum-
ably the P261L mutation is relatively mild since the het-
NOTE ADDED IN PROOFerozygous father excretes cystine in the normal range
and the proband (who also inherited the dominant The mutation reported by the International Cystinuria
799insA frameshift mutation from his mother) excretes Consortium as c.800-801insA was in fact c.799-800insA.
cystine in the range of his mother and maternal grandfa- Consequently, it is the same mutation (799insA) as that
ther who have only the 799insA change (Fig. 4). identified in this report (communicated by M. Palacin,
The intronic change, IVS9-17G→A, was observed in International Cystinuria Consortium).
patient AW (#872-01; Type I/III) who also carried the
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